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Histone deacetylase (HDAC) inhibitors are known to arrest human tumor cells at the G1 phase of the cell cycle and activate the cyclin-dependent kinase inhibitor, p21 WAF1/Cip1 . However, several studies have suggested the existence of a p21 WAF1/Cip1 -independent molecular pathway. We report here that HDAC inhibitors activate a member of the INK4 family, the INK4d gene, causing G1 phase arrest, in the human T cell leukemia cell line, Jurkat. One of the major Trichostatin A (TSA)-responsive elements is a specific Sp1 binding site in the INK4d promoter. Electrophoretic mobility-shift assay revealed that Sp1 and Sp3 can specifically interact with this Sp1 binding site. Furthermore, using chromatin immunoprecipitation assay, we demonstrated that HDAC2 was present in the INK4d proximal promoter region in the absence, but not the presence, of TSA. Taken together, these results suggest that treatment with TSA transcriptionally activates INK4d by releasing HDAC2 from the histone-DNA complex at the INK4d promoter. Using a p21 WAF1/Cip1 -deleted human colorectal carcinoma cell line, HCT116 p21 (À/À), we show that upregulation of p19
INK4d by TSA is associated with inhibition of cell proliferation. Moreover, mouse embryo fibroblasts lacking Ink4d were resistant to the growth inhibitory effects of TSA as compared to their wild-type counterpart. Our findings suggest that p19
INK4d in addition to p21
Introduction The use of histone deacetylase (HDAC) inhibitors has revealed a complex role of HDAC in cellular function, because these agents have been reported to arrest the cell cycle at G1 or G2 phase (Yoshida and Beppu, 1988) or to induce differentiation and apoptosis (Yoshida et al., 1995; Chang and Yung, 1996) . Their clinical applications have been initiated in a phase II study testing depsipeptide, a novel cyclic peptide inhibitor of histone deacetylase, in patients with T-cell lymphoma (Piekarz et al., 2001) . Therefore, HDAC inhibitors are one of the most attractive and promising antitumor agents. Some of the molecular mechanisms of the G1 phase arrest caused by HDAC inhibitors has been reported previously. Cell-cycle progression is regulated by cyclindependent kinases (CDKs) that form complexes with cyclin in a phase-specific manner during the cell cycle (Sherr, 1993) . Cyclin D-CDK4/6 and cyclin E-CDK2 play important roles in promoting the transition from the G1 phase to the S phase of the cell cycle by phosphorylating the tumor suppressor retinoblastoma protein (pRB) (Dowdy et al., 1993; Sherr, 1993) . Activation of cyclin/CDKs is counterbalanced by CDK inhibitors (CKIs). The first family of CKIs, referred to as the CIP/KIP family, consists of related proteins known as p21 WAF1/Cip1 , p27
Kip1 and p57
Kip2
, and each member inhibits a broader spectrum of cyclin/ CDK complexes (Xiong et al., 1993; Sherr and Roberts, 1999) . Previously, we demonstrated that HDAC inhibitors, such as sodium butyrate and Trichostatin A (TSA), inhibit cellular proliferation and induce the expression of WAF1/Cip gene in a p53-independent manner. Furthermore, we reported that these agents activate the promoter of WAF1/Cip1 through specific Sp1 sites Sowa et al., 1997) . Others previously reported that p21 WAF1/Cip1 is the critical mediator of butyrate-induced growth arrest using a p21 WAF1/Cip1 -deleted human colorectal carcinoma cell line, HCT116 p21 (À/À) (Archer et al., 1998) . However, p21 (À/À) mouse embryo fibroblasts (MEFs) also underwent butyrate-induced growth arrest at the G1 phase of the cell cycle (Vaziri et al., 1998) . Moreover, the growth of HCT116 p21 (À/À) was still inhibited by TSA (Kim et al., 2000) . These reports strongly suggest HDAC inhibitors induced-growth arrest can be mediated by a p21 WAF1/Cip1 -independent molecular pathway.
The second family of CKIs is called the INK4 family (for inhibitors of Cdk4) proteins . The four members of  the INK4 family, designated as p16   INK4a   , p15   INK4b   ,  p18 INK4c and p19
INK4d
, specifically and directly bind to CDK4/6 and inhibit their activity (Serrano et al., 1993; Hirai et al., 1995; Sherr and Roberts, 1999) . It remains to be elucidated whether any members of the INK4 family are involved in G1 phase arrest induced by HDAC inhibitors. Our results demonstrate that the HDAC inhibitor, TSA, activates INK4d mRNA and its protein, p19
INK4d in a dose-dependent manner in the human T cell leukemia cell line, Jurkat. In addition, we observed that these HDAC inhibitors can activate the INK4d gene promoter. Using a series of mutant INK4d promoter constructs, we found that one Sp1 site at À263 and À254 relative to the first base of the translation initiation codon is involved in the transactivation of the INK4d promoter by TSA. Electrophoretic mobility-shift assay (EMSA) using Jurkat cells revealed that Sp1 and Sp3 do specifically interact with this Sp1 binding site. Using chromatin immunoprecipitation assay, we confirmed that Sp1 and Sp3 were associated with the endogenous INK4d proximal promoter region in Jurkat cells. Furthermore, HDAC2 was also present in the INK4d proximal promoter region in the absence but not in the presence of TSA. To rule out the influence of p21 WAF1/Cip1 on TSA-mediated cell growth inhibition, and to confirm that p19
Ink4d is important in TSA-induced G1 arrest, we tested the effect of growth inhibition by TSA, using a p21 WAF1/Cip1 -deleted cell line HCT116 p21 (À/À) and MEFs lacking Ink4d, respectively (Zindy et al., 2000) . We demonstrated that TSA also activated INK4d in a dose-dependent manner in cells lacking WAF1/Cip1 and that MEFs lacking Ink4d were resistant to the growth inhibitory effects of TSA.
Results

TSA induces growth arrest at the G1 phase in cell-cycle progression in Jurkat human T cell leukemia cells
We first examined the effect of TSA on the proliferation of Jurkat cells. Figure 1 shows the growth of Jurkat cells in the presence or absence of various concentrations of TSA. TSA inhibited the proliferation of Jurkat cells in a dose-dependent manner and 240 nM TSA had a cytostatic effect. To investigate the effect of TSA on the cellcycle progression of Jurkat cells, the DNA content was measured by flow cytometric analysis. Treatment with 240 nM of TSA for 36 h increased the percentage of the G1 phase from 48 to 58%, increased the G2/M phase from 11 to 28%, and decreased the S phase from 41 to 14% (data not shown). These data demonstrate that TSA arrests the cell cycle of Jurkat cells at the G1 phase. Among the INK4 family, both p18  INK4c and p19  INK4d are  normally expressed, whereas p16 INK4a and p15 INK4b are homozygously deleted in Jurkat cells (Borgonovo et al., 1996; Suzuki et al., 1999) . In this study, we investigated whether HDAC inhibitors inhibit cell growth through INK4d in Jurkat cells. We found that TSA treatment of Jurkat cells for 24 h stimulates the expression of INK4d mRNA in a dose-dependent manner up to four-fold compared with untreated cells (Figure 2a ). These data are consistent with the above result showing that TSA inhibited the growth of Jurkat cells in a dose-dependent manner. Time course studies showed that INK4d mRNA was upregulated 3 h after treatment with 240 nM TSA and reached its peak about 6-12 h after treatment ( Figure 2b) .
TSA increases INK4d mRNA and protein levels in Jurkat cells
Next, we wanted to elucidate whether the p19 Ink4d induces G1 phase arrest by blocking Cdk4/6 kinase activity and pRB phosphorylation (Hirai et al., 1995) , we tested by Western blotting whether TSA altered the phosphorylation of pRB protein. We found that at about 36 h after treatment, hyperphosphorylated forms of pRB protein began to be converted into a hypophosphorylated form (Figure 2e ).
TSA stimulates INK4d promoter activity
As INK4d mRNA expression is induced by TSA in Jurkat cells, we investigated whether TSA could transactive the 
Analysis of the TSA-responsive elements in the INK4d promoter
We then tried to determine which regions of the INK4d promoter were responsive to TSA. For this purpose, we generated a series of 5 0 deletions in the promoter region, p19 (À856/À2), p19 (À536/À2), p19 (À251/À2), and p19 (À126/À2). The resulting plasmids were transiently transfected into Jurkat cells, and the luciferase activities following TSA treatment were measured. As shown in Figure 4a , luciferase activity from p19 (À536/À2) as well as p19 (À856/À2) was activated about 11-to 13-fold by 240 nM TSA, a level similar to that of the activation using the full-size promoter, p19 (À3814/À2). On the other hand, activation by 240 nM TSA using p19 (À251/ À2) decreased to 4.2-fold. These results suggest that the major TSA-responsive elements are located within a 285-bp region between À536 and À252 relative to the first base of the translation initiation codon (Figure 4a ).
Using a series of 5 0 deletion constructs within the 285-bp region of the INK4d promoter, we analysed where the major TSA-responsive elements were located. As shown in Figure 4b , the luciferase activity from the p19 (À263/À2) construct was activated 7.1-fold by 240 nM TSA, a level similar to the activation found with the fullsize promoter, construct p19 (À3814/À2). On the other hand, the activation by 240 nM TSA using the p19 (À251/À2) plasmid decreased to 2.9-fold. These results suggest that one of the most important TSA-responsive elements was located between À263 and À252. This 12-bp region harbors only one consensus-binding site for the transcription factor Sp1 (Figure 4c ).
To determine whether this Sp1 binding site is responsible for the transactivation of the INK4d promoter by TSA, we generated a mutant of the deleted construct, p19 (À263/À2), by mutating the Sp1 site, and called it p19 (À263/À2)-mtSp1 ( Figure 4c ). Wild-type and mutant plasmids were transiently transfected into Jurkat cells, and their luciferase activities were assayed in the presence or absence of 240 nM TSA. As shown in Figure 4c , activation by TSA using p19 (À263/À2)-mtSp1 decreased from 10.8-to 4.2-fold; the reduction in activity was approximately the same as that observed with deleted region. To more precisely examine the role of this Sp1 binding site in INK4d promoter activation by TSA, a mutation of the Sp1 site was also introduced into the full-size promoter construct (p19 (À3814/À2)). We termed this new construct, p19 (À3814/À2)-mt Sp1. As shown in Figure 4c , the activation by TSA in p19 (À3814/À2)-mt Sp1 decreased to 5.6-fold from the 8.9-fold activation seen in wild-type p19 (À3814/À2).
Taken together, we conclude that this Sp1 binding site located between À263 and À254 relative to the first base of the translation initiation codon is necessary for the activation of the INK4d promoter in response to TSA.
Identification of proteins interacting with the major TSA-responsive element
To identify the trans-acting factor(s) that interact with the major TSA-responsive element, we performed EMSA using [ the Sp1 site. Nuclear extracts were purified from either TSA-treated or untreated Jurkat cells. As shown in Figure 5 , three shifted bands were observed when the probe was incubated with the Jurkat cell nuclear extract. All three bands were competed out by excess unlabeled WTÀ268/À249, but not MUTÀ268/À249, in which the Sp1 site had been mutated. These data suggest that all three bands are specific. Supershift experiments in the presence of Sp1-antibody showed that the slowestmigrating complex was shifted. Both the fastest-migrating complex and slow-migrating complex, which ran slightly faster than the slowest-migrating complex of Sp1, were diminished in the presence of Sp3-antibody. However, TSA treatment did not significantly change the DNAbinding activities of either Sp1 or Sp3.
The endogenous INK4d promoter is associated with Sp1 and Sp3
To directly test whether Sp1 and Sp3 were associated with the INK4d proximal promoter region in vivo, chromatin immunoprecipitation (ChIP) assay was performed with antibodies against Sp1, Sp3 and a-Tubulin (unrelated antibody) ( Figure 6a ). As a positive control, a three-fold dilution of total input DNA in the absence or presence of TSA was used for the PCR reactions ( Figure 6a, lanes 1 versus 2) . Both Sp1 and Sp3 were associated with the endogenous INK4d promoter whereas a-Tubulin was not (Figure 6a ). We further examined Jurkat cells by ChIP assay after treatment with TSA. Consistent with our EMSA results, the occupancy of the INK4d promoter by Sp1 or Sp3 did not significantly change after treatment with TSA ( Figure 6a , lanes 5 versus 6, 7 versus 8).
HDAC2 is present in the INK4d proximal promoter region in the absence but not the presence of TSA Recently, Sp1 and Sp3 were reported to be associated with HDAC1 and HDAC2 in several promoters (Choi et al., 2002; Sun et al., 2002; Won et al., 2002; Zhang and Dufau, 2002) . To precisely analyse the mechanism of transcriptional activation of INK4d by TSA, we used a ChIP assay to investigate whether HDAC1 and/or HDAC2 are present in the INK4d proximal promoter region. Anti-HDAC2 antibody was able to immunoprecipitate the INK4d proximal promoter region in the absence but not the presence of TSA (Figure 6a , lanes 11 versus 12). In contrast, little amplification was observed when DNA immunoprecipitated by anti-HDAC1 antibody was used as a template in either the absence or presence of TSA (Figure 6a, lanes 9 versus 10) .
We next examined whether treatment with TSA suppressed the expression of the HDAC2 protein in Jurkat cells. Treatment with TSA did not change the expression of the HDAC2 protein (Figure 6b ). These results indicate that TSA treatment reduces the capacity of HDAC2 to bind the histone-DNA complex containing Sp1 and Sp3 in the INK4d proximal promoter region. -deleted human colorectal carcinoma cell line, HCT116 p21 (À/À) was used. In HCT116 p21 (À/À) cells, TSA also effectively suppressed cell growth (Figure 7a ). At 24-h treatment of TSA caused both G 1 and G 2 -M phase cell-cycle arrest (data not shown). TSA treatment also increased p19
INK4d protein levels in a dose-dependent manner (Figure 7b ) and, subsequently, 
Overexpression of p19
INK4d inhibits cell growth of Jurkat cells
We examined the effect of p19
INK4d overexpression on cell proliferation of Jurkat cells. Jurkat cells were cotransfected with a mammalian expression vector encoding human INK4d full-length cDNA and a vector encoding a neomycin gene conferring resistance to G418. Recovery of antibiotic-resistant Jurkat cells was markedly inhibited by overexpression of p19
INK4d
, yielding 40% of resistant colonies compared to a control empty vector (Figure 8a) . Furthermore, the expression of the p19
INK4d protein significantly increased 24 h after transfection in Jurkat cells (Figure 8b ). These results demonstrate that overexpression of p19
INK4d inhibits the proliferation of Jurkat cells.
Effect of TSA on the growth of wild-type or Ink4d-deficient MEFs
To analyse the physiological relevance of the induction of p19
INK4d in TSA-induced growth arrest, we examined the effects of TSA on cell proliferation of wild-type and Ink4d-deficient [p19(À/À)] MEFs. p19(À/À) MEFs grew more rapidly than wild-type MEFs in the absence of TSA ( Figure 9a ). As expected, Ink4d-null MEFs were more resistant to the growth inhibitory effects of TSA than were their wild-type counterparts on days 3-5 (Figure 9a and b) .
Taken together, these results suggest that loss of p19
INK4d influences the cellular response to the antiproliferative effects of TSA and that the activation of p19
INK4d is involved in growth inhibition induced by HDAC inhibitors.
Discussion
The role of the CIP/KIP family of proteins in the antitumor effects of HDAC inhibitors has been intensively studied. Indeed, activation of p21 WAF1/Cip1 in a p53-independent manner is one of the most important molecular mechanisms of butyrate-induced G1 phase arrest . It was previously shown that p21 WAF1/Cip1 is required for butyrate-mediated growth inhibition of HCT116 p21 (À/À) (Archer et al., 1998) . However, several studies have recently suggested the existence of a p21 WAF1/Cip1 -independent mechanism of G1 phase arrest by HDAC inhibitors (Vaziri et al., 1998; Kim et al., 2000) . Moreover, MEFs deficient in both p21 WAF1/Cip1 and p27 Kip1 were still growth inhibited by TSA (Wharton et al., 2000) . These data suggest that the inhibitory actions of TSA on proliferation of MEFs were largely independent of any direct modulation of p21 WAF1/Cip1 or p27
Kip1
. We therefore examined whether CKI members of the INK4 family were associated with induction of cell-cycle arrest by TSA. In the present study, we found that treatment of Jurkat cells with TSA, at concentrations that induce cytostatic effects, significantly enhanced both INK4d mRNA expression and the p19
INK4d protein levels, resulting in G 1 phase arrest. MEFs lacking Ink4d were more resistant to TSA-induced proliferation arrest but not totally so. This raised the possibility that other CKIs might also be involved in G1 phase arrest induced . We found that p18
INK4c is also induced by TSA in Jurkat cells (data not shown).
We next investigated the molecular mechanism of INK4d gene activation by TSA. To clarify whether the activation of the INK4d promoter was responsible for the upregulation of its mRNA, we analysed the transcriptional regulation of the INK4d gene by TSA, using its promoter region that we recently cloned (Matsuzaki et al., 2002) . TSA actually stimulates INK4d promoter activity in Jurkat cells. One of the major TSAresponsive elements is an Sp1 binding site at À263 and À254 relative to the first base of the translation initiation codon in the INK4d promoter. EMSA revealed that Sp1 and Sp3 specifically interacted with this Sp1 binding site. However, the intensity and mobility pattern of the retarded bands were not significantly changed by TSA, which suggests that the activation of the INK4d promoter by TSA is not due to an increase in the binding of Sp1 or Sp3. These results are consistent with our previous reports Sowa et al., 1999) and those of others (Datto et al., 1995) on the WAF1/Cip1 promoter.
In addition, ChIP assays confirmed that Sp1 and/or Sp3 could bind the Sp1 binding site of the INK4d promoter in vivo. Our results suggest that both Sp1 and Sp3 were binding the endogenous INK4 proximal promoter region in either the absence or the presence of TSA, which is consistent with our EMSA results. These results further indicate that the TSA-mediated increase in INK4d promoter activity in Jurkat cells was not caused by the increased recruitment of Sp1 or Sp3 to the INK4d promoter in vivo.
Numerous studies have suggested that acetylation and deacetylation of histones may have important roles in gene expression (Wolffe and Pruss, 1996) . HDACs form complexes with several transcriptional corepressors, including mSin3A, N-CoR and SMRT, and HDACcorepressor complexes act as transcriptional repressors and suppress gene expression (Chen and Evans, 1995; Alland et al., 1997; Heinzel et al., 1997) . Recently, several reports have revealed direct or indirect interaction between Sp1/Sp3 with HDAC1 and HDAC2 (Choi et al., 2002; Sun et al., 2002; Won et al., 2002; Zhang and Dufau, 2002) . These reports suggest that it would be important to consider the interaction of HDACs with (Choi et al., 2002) . Recently, another report revealed that the tumor suppressor p53 and HDAC1 are antagonistic regulators of the WAF1/Cip1 promoter, competing with each other to bind to Sp1/Sp3 (Lagger et al., 2003) . This raises the possibility that any transcriptional coactivator may compete with HDAC2 to bind to Sp1/Sp3, leading to histone acethylation and concomitant expression of INK4d. Therefore, we hypothesize that treatment with TSA inhibits the transcriptional repressive effect of HDAC2, by releasing HDAC2 from the Sp1/Sp3 transcriptional factor complex at the INK4d promoter. Our results and those of others suggest that transcriptional regulation by TSA depends on proteins that can form complexes and influence Sp1 and/or Sp3-mediated transcription.
To rule out the influence of p21 WAF1/Cip1 on TSAmediated cell growth inhibition, we investigated the effects of growth inhibition by TSA in a p21 WAF1/Cip1 -deleted cell line, HCT116 p21 (À/À). Kim et al. (2000) previously compared TSA-sensitivity between p21 ( þ / þ ) and p21 (À/À) clones of HCT116 cells and found that HCT116 p21 (À/À) cells were significantly resistant to TSA, but that their growth was still inhibited by TSA at high concentrations. These studies were followed by our own showing that 120 nM TSA had a cytostatic effect on HCT116 p21 (À/À) cells and that TSAtreatment activated the INK4d mRNA and the p19 INK4d protein in a dose-dependent manner. Our results suggest that WAF1/Cip1 gene expression is not indispensable for the G1 phase arrest induced by TSA and that the INK4d . We have two lines of evidence that shows the physiological relevance of p19
INK4d expression. First, overexpression of p19
INK4d inhibited cell proliferation of Jurkat cells. Second, MEFs in which Ink4d was lost exhibited decreased TSA sensitivity relative to their normal counterparts, further supporting a model in which the endogenous Ink4d gene is involved in TSA-mediated cell growth inhibition.
As to the possibility that other INK4 family members are involved in the growth arrest by TSA in HCT116 p21
-deleted cells, we found that p18
INK4c (in preparation for submission) and p15
INK4b (Hitomi et al., 2003) are induced by TSA in HCT116 p21-deleted cells.
In summary, our results suggest that the activation of p19
INK4d and other INK4 family genes contributes to G1-growth arrest induced by TSA and that the molecular mechanism of activation of the INK4d gene promoter is mediated through a specific Sp1 site. Recently, we proposed a novel approach for chemotherapy or chemoprevention against cancer, which we termed 'gene-regulating chemotherapy' or 'gene-regulating chemoprevention' (Sakai, 1996; Sowa and Sakai, 2000) . Our strategy is to activate the potent function of growth-inhibitory genes, which can compensate for p16
INK4a loss by deletion or mutation commonly found in human tumors (Ruas and Peters, 1998) . The INK4d gene is one of the best candidates, because p19
INK4d has functional similarity to p16
INK4a as a member of the INK4 family (Guan et al., 1996) and its normal expression appears to be conserved in many cancer cells . Therefore, transcriptional activation of the INK4d gene by chemotherapeutic agents may be of great significance in the therapy or the prevention of malignant tumors that harbor a deletion or mutations in INK4a.
Materials and methods
Cell culture, cell proliferation studies and treatment with TSA The human T lymphoblastic T cell line, Jurkat (a kind gift from Dr JI Fujisawa, Kansai Medical University) was maintained in RPMI 1640 medium with 10% fetal bovine serum and incubated at 371C in a humidified atmosphere of 5% CO 2 . The p21 WAF1/Cip1 -deleted human colorectal carcinoma cell line, HCT116 p21 (À/À) (a kind gift from Dr B Vogelstein, Johns Hopkins University School of Medicine, Baltimore, USA) was maintained in DMEM supplemented with 10% fetal bovine serum and incubated at 371C in a humidified atmosphere of 5% CO 2 . Wild-type and Ink4d-deficient MEFs were maintained in DMEM supplemented with 10% fetal bovine serum, 2 mM glutamine, 0.1 mM MEM nonessential amino acids, 55 mM 2-mercaptoethanol and 10 mg/ml gentamycin, and incubated at 371C in a humidified atmosphere of 9% CO 2 . For the cell proliferation studies, cells were plated at a density of 5 Â 10 4 cells in 25-mm-diameter dishes (Jurkat) or 35-mmdiameter dishes (HCT116 p21 (À/À) or MEFs). At 24 h after cell plating, various concentrations of TSA (Wako, Osaka, Japan) were added to the culture medium. From the first day to the fourth (Jurkat or HCT116 p21 (À/À)) or the fifth (MEFs) day after plating, the number of viable cells was counted by trypan-blue dye exclusion.
Analysis of cell-cycle progression
Unsynchronized cells were exposed to TSA for 24 h [HCT116 p21 (À/À)] or 36 h (Jurkat) and harvested. Cells were fixed in 70% ethanol, treated with RNase, and nuclei were stained with propidium iodide before their DNA content was measured using a Becton Dickinson FACScaliber (Becton Dickinson, Mountain View, CA, USA).
Plasmid preparation
As previously reported, the human p19
INK4d
-luciferase fusion reporter plasmid was termed p19 (À3814/À2) (Matsuzaki et al., 2002) . Deletion mutants of human p19 (À3814/À2), termed p19 (À856/À2), p19 (À536/À2), p19 (À318/À2), p19 (À263/ À2), p19 (À251/À2) and p19 (À126/À2), were generated using a Mungbean-Exonuclease III system from the Kilo-sequence Deletion Kit (Takara, Tokyo, Japan). Two different reporter plasmids, p19 (À3814/À2)-mt Sp1 and p19 (À263/À2)-mt Sp1, with a mutation in the Sp1 binding site at À263/À254 were generated by site-directed mutagenesis using the Quick Change XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) with synthesized oligonucleotides as follows: p19 (À3814/À2)-mt Sp1: sense, 5 0 -ACCCGGCCCCCAAGGTT-TTGGCGCCGGGCAGG-3 0 ; and antisense, 5 0 -CCTGCCCG-GCGCCAAAACCTTGGGGGCCGGGT-3 0 ; p19 (À263/À2)-mt Sp1: sense, 5 0 -CTCTATCGATAGGGTTTTGGCGCCG-GGCAGGGCCCC-3 0 and antisense, 5 0 -GGGGCCCTGCC-CGGCGCCAAAACCCTATCGATAGAG-3 0 . Each sequence is identical to that of p19 (À3814/À2) or p19 (À263/À2) except for the sequence in bold letters (Figure 4c ). The generated constructs were confirmed by sequencing. Human p19 INK4d expression vector (pMH4p19) and its control vector (pMH4) were gifts from Dr Frank L Graham, McMaster University, Canada (Schreiber et al., 1999) . A vector encoding a neomycin resistance gene (pCD0) was a gift from CW Miller, UCLA School of Medicine, Los Angeles, USA.
RNA isolation and Northern blot analysis
Total RNA was isolated from cells grown in a 100-mm diameter dish using a Sepasol RNA isolation kit (Nacalai Tesque Inc., Kyoto, Japan), and 10 mg of total RNA per lane was used for Northern blot analysis. The p19 cDNA used for the probe was amplified by PCR, using human spleen cDNA as a template based on the data in GenBank No. NM_001800. Northern blot analysis was performed using standard methods (Sambrook and Russell, 2001 ). The mRNA level was determined using a Fuji Image Analyser Bas 2000 (Fujix, Tokyo, Japan).
Protein isolation and Western blot analysis
Cells were lysed by100 ml of RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate). The protein extract was boiled for 5 min and loaded onto a 12% (for p19
INK4d and HDAC2 detection) or 7% (for pRB detection) polyacrylamide gel, electrophoresed and transferred onto a nitrocellulose membrane. A mouse monoclonal antibody to human p19 (DCS-100 from NeoMarkers, Union City, CA, USA), a rabbit polyclonal antibody to human p19 (C-20 from Santa Cruz Biotechnology, Santa Cruz, CA, USA), pRB (PM-14001A from Pharmingen, BectonDickinson Franklin Lakes, NJ, USA) or to HDAC2 (51-5100, Zymed Laboratories Inc.) were used as the primary antibody. The signal was then detected with the enhanced chemiluminescence system (ECL; Amersham Pharmacia Biotech, UK limited).
Transient transfection and luciferase assay
Jurkat cells were transfected by the DEAE-dextran method as described previously (Fujisawa et al., 1985) . At 24 h after transfection, TSA was added, and 48 h after the transfection, the cell lysates were collected for a luciferase assay. Cells were washed twice with PBS and resuspended in 100 ml of 0.25 M Tris-HCl (pH 7.5). Five cycles of freeze-thawing were performed in liquid nitrogen/water at 371C. Luciferase activities were normalized for the amount of protein in the cell lysates. For clonogenic assay, pMH4p19 or pMH4 was cotransfected with pCD0 at a ratio of 1 : 3 into Jurkat cells by electroporation (Gene Pulser, Bio-Rad). Jurkat cells in 400 ml RPMI medium without serum were electroporated at 41C with a total of 40 mg DNA at 310 V, 975 mF in 0.4 cm cuvettes (BioRad). Clonogenic survival was determined by cloning in soft agar as described below.
Preparation of nuclear extracts and EMSA
Nuclear extracts of Jurkat cells were prepared as described previously (Sowa et al., 1999) . Annealed oligonucleotides containing the sequences between positions À268 and À249 from the first base of the translation initiation codon of the INK4d promoter (sense, 5 0 -AGCTCCCAAGGGGCGGGC-GCCGGG-3 0 and antisense, 5 0 -TCGACCCGGCGCCCG-CCCCTTGGG-3 0 ) were labeled with [a-32 P]dCTP using the Klenow fragment of Escherichia coli DNA polymerase and were used as the probe. The reaction mixture for the EMSA contained 8 mM Tris-HCl (pH 7.9), 24 mM HEPES-KCl (pH 7.9), 120 mM KCl, 24% glycerol, 2 mM EDTA, 2 mM DTT, 1.5 mg of poly (dI dC) (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA), and 8 mg of nuclear extract. After preincubation for 5 min, the indicated cold competitors or antibodies were added to the mixture, and the binding reaction was allowed to proceed at 41C for 30 min. The reaction mixture was further incubated for 30 min in the presence of [ 32 P]labeled probe DNA. Anti-Sp1 and anti-Sp3 antibody were from Santa Cruz Biotechnology, Santa Cruz, CA, USA. The sequences of the top strands of oligonucleotides used in competition analysis are as follows, with mutations indicated by underlines: 5 0 -AGCTCCCAAGGGGCG-GGCGCCGGG-3 0 ; MUTÀ268/À249, 5 0 -AGCTCCCAA-GGTTTTGGCGCCGGG-3 0 . The product was resolved by electrophoresis on a 3% native polyacrylamide gel, 0.3 Â TBE nondenaturing gel at 41C for 100 min, and analysed with a Fuji Image Analyser Bas 2000 (Fujix, Tokyo, Japan).
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed using the ChIP assay kit (Upstate Biotechnology) according to the manufacturer's instructions. Cells were fixed in normal culture medium with formaldehyde at a final concentration of 1% for 10 min at 371C. Sonication was performed to achieve an average DNA length of 500-1000 bp. The following antibodies were used for the immunoprecipitation of the crosslinked chromatin: anti-Sp1 (sc-59, Santa Cruz Biotechnology), anti-Sp3 (sc-644, Santa Cruz Biotechnology), anti-HDAC1 (sc-8410, Santa Cruz Biotechnology), and anti-HDAC2 (51-5100, Zymed Laboratories Inc.). Anti-a-Tubulin (CP06, oncogene RESEARCH PRO-DUCTS) was used as a nonrelated antibody for the immunoprecipitation of the endogenous proteins. DNA isolated from the immunoprecipitates was then subjected to PCR amplification using the GC-RICH PCR System (Roche Molecular Biochemicals). PCR was carried out as follows: 1 cycle at 951C for 3 min; 25 cycles at 951C for 30 s, 581C for 30 s, 721C for 20 s; and 1 cycle at 721C for 7 min, using primers 5 0 -CAATCAGGAGCGACGCGT-3 0 and 5 0 -CCTCCAGCAG-CATGTCGAC-3 0 that amplify the region between nucleotides À557 and þ 13 within the INK4d proximal promoter. Then, nested PCR was carried out as follows: one cycle at 951C for 3 min; 44 cycles at 951C for 30 s, 621C for 30 s, 721C for 20 s; and one cycle at 721C for 7 min, using nested primers 5 0 -AAAACAAATCAGCGGCGTTC-3 0 and 5 0 -GCTCCTCC-CCCTGTCAGC-3 0 that amplify the region between nucleotides À413 and À172 within the INK4d proximal promoter. The amplified 242-bp DNA fragment was separated on 2% agarose gel and visualized with ethidium bromide. The detected band was confirmed by sequencing.
Clonogenic assay pMH4p19 or pMH4 was co-transfected with pCD0 into Jurkat cells as described above. Following 3-day maintenance in RPMI after transfection, the ability of cells to form colonies in soft agar was determined. An equal proportion of each culture was diluted in a total volume of 5 ml Iscoves medium (Sigma) containing 20% (v/v) fetal calf serum, 10% (v/v) Jurkat conditioned medium as appropriate, and 0.3% (w/v) noble agar (Difco) and plated in 60-mm dishes. Once set, dishes were overlaid with 2.5 ml Iscoves medium containing supplements and incubated for 3 weeks at 371C in 5% CO 2 before counting colonies. G418 (Nacalai Tesque Inc., Kyoto, Japan) was added to the medium to a final concentration of 1 mg/ml. Abbreviations HDAC, histone deacetylase; TSA, Trichostatin A; EMSA, electrophoretic mobility-shift assay.
